Biostax Corp. engages in the acquisition, development, and commercialization of pharmaceutical and biotechnology products. Its partnered programs include JKB-122, Londonal, and Low Dose Naltrexone. The company was founded by Noreen Griffin on December 2, 1993 and is headquartered in Winter Park, FL.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company